51345-81-4

Basic information

• Product Name: 1-<4-(benzyloxy)phenyl>-3-piperidinopropan-1-one
• Synonyms: 1-<4-(benzyloxy)phenyl>-3-piperidinopropan-1-one
• CAS NO: 51345-81-4
• Molecular Weight: 323.435
• Mol File: 51345-81-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-<4-(benzyloxy)phenyl>-3-piperidinopropan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-<4-(benzyloxy)phenyl>-3-piperidinopropan-1-one(51345-81-4)
• EPA Substance Registry System: 1-<4-(benzyloxy)phenyl>-3-piperidinopropan-1-one(51345-81-4)

Safety Data

• Hazardous Substances Data: 51345-81-4(Hazardous Substances Data)

Usage

Type

Synthetic cannabinoid

Family

Designer drugs

Receptors

Acts as a potent agonist for cannabinoid receptors CB1 and CB2

Effects

Leads to psychoactive effects when consumed

Adverse Health Effects

Respiratory depression, seizures, and even death in some cases

Legal Status

Banned in a number of countries

Classification

Controlled substance in several jurisdictions

Regulation

Production and distribution are strictly regulated due to potential for misuse and harm to public health

Upstream product

• 6793-92-6 p-benzyloxyphenylbromide 
• 405212-52-4 N-methoxy-N-methyl-3-(piperidine-1-yl)propanamide 
• 110-89-4 piperidine 
• 50-00-0 formaldehyd 
• 54696-05-8 4'-benzyloxy-acetophenone 

Downstream Products

• 51345-82-5 1-<4-(benzyloxy)phenyl>-3-piperidinopropan-1-one hydrochloride 

Relevant articles and documents

Setup and validation of a reliable docking protocol for the development of neuroprotective agents by targeting the sigma-1 receptor (S1R)

Sigma-1 receptor (S1R) is a promising molecular target for the development of novel effective therapies against neurodegenerative diseases. To speed up the discovery of new S1R modulators, herein we report the development of a reliable in silico protocol suitable to predict the affinity of small molecules against S1R. The docking method was validated by comparing the computational calculated Ki values of a test set of new aryl-aminoalkyl-ketone with experimental determined binding affinity. The druggability profile of the new compounds, with particular reference to the ability to cross the blood–brain barrier (BBB) was further predicted in silico. Moreover, the selectivity over Sigma-2 receptor (S2R) and N-methyl-d-aspartate (NMDA) receptor, another protein involved in neurodegeneration, was evaluated. 1-([1,1′-biphenyl]-4-yl)-4-(piperidin-1-yl)butan-1-one (12) performed as the best compound and was further investigated for acetylcholinesterase (AchE) inhibitor activity and determination of antioxidant activity mediated by aquaporins (AQPs). With a good affinity against both S1R and NMDA receptor, good selectivity over S2R and favorable BBB penetration potential together with its AChE inhibitory activity and its ability to exert antioxidant effects through modulation of AQPs, 12 represents a viable candidate for further development as a neuroprotective agent.

Synthesis of several benzyloxphenyl derivatives with local anesthetic activity (author's transl)

Several 2- and 4-benzyloxy- and 4-(2'- and 4'-substituted) benzyloxy-beta-substituted amino-propiophenones, some of the corresponding alcohols, some 4-benzyloxy-alpha-substituted amino-acetophenones were synthetised and tested for their pharmacological activity.